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HOST CELLS infiltrating tumours have
been observed for many vears, but have
recently become the subject of increasing
interest (rev. by Haskill et al., 1978).
ITarious types of lymphoid cells aiid
macrophages have been separated from
tumours, and have been shown to have
anti-tumour effects in vitro (Holden et al.,
1976; Gillespie & Russell, 1.978; ffaskill
et al., 1978). Hitherto, however, there has
been little evidence of the relevance of
these in vitro activities to the control of
tumour growth in vivo. We report here
experiments showing that lymphoid cells
from within a progressively growing rat
fibrosarcoma can prevent tumour growth
when injected in admixture with sarcoma
cells in a Winn assay.
These studies were performed using a
3-methyleholanthrene-induced sarcoma
(Mc7)transplanted s.c. insyngeneicWAB/
Not rats. This tumour has previously been
shown to be immunogeiiic (Baldwin et al.,
1971), immunized rats being capable of
rejecting 2 x 1.06 viable tumour cells,
whilst the minimum inoculum for growth
in unimmunized rats is 3 x 105 cells. In the
experiments described here, tumours used
as a source oflymphoid cells were taken 10
days after s.c. injection of 106 tumour cells
into normal syngeneic rats. Tumours
were removed, dissected free of fibrous
tissue, and finely diced. Tissue was com-
pletely disaggregated by repeated stirring
with 0-25% trypsin (Difco) and the cells
collected by centrifugation (120 g for 10
min), washed twice in Hanks' balanced
salt solution (HBSS) and resuspended in
Eagle's minimum. essential medium
buffered with Hepes and containing 5%
heat-inactivated foetal calf serum (MEM-
FCS).
Lyniphoid cells were separated by
passage through columns containino, 1-2 g
nylon fibre (Fenwall Leucopac) in 20ml
syringe barrels. After equilibration of the
columns for I h at 37T in MEM-FCS, 108
tumour cells in 3ml MEM-FCS were added
and incubated for 45 niin at 37T. Cells
were then eluted at a rate of 0-5 ml/min,
the flow rate used being critical; faster
elution causes contaminatioii of eluted
cells with sarcoma cells, and slower
elution reduces the yield of lymphoid
cells. Under these conditions, 108 tumour
cells yield 3-5 x 106 host cells, containing
less than 2% contaminating sarcoma cells;
- 50% ofthelymphoid cellsinthe tumour-
cell suspension are recovered. Host cells
consisted predominantly oflymphoid cells
(less than 0-5% macrophages), ofwhich up
to 50% bear the W3/13 T-cell marker
(Williams el al., 1977). Spleen cells from
normal WAB/Not rats, either untreated,
or trypsinized and nylon-column eluted as
described above, were used as a control
lymphoid-cell population. Cells were
washed twice in HBSS before use in Winn
assays.
Target Mc7 cells for use in Winn assays
were prepared from tumours passaged by
s.c. grafts. Tumour tissue was removed,
washed in HBSS and disaggregated by
trypsinization as described above, except
that cells were centrifuged at 60 q to
minimize damage to sarcoma cells; this947 TUMOUR INHIBITION BY INTRINSIC LYMPHOID CELLS
also produces a lower proportioii of
lymphoid cells in the tumour-cell prepara-
tions (tumour target-cell preparations
contained -5% lymphoid cells). Foi-
Wiiin assavs, rats were inoculated s.c. on
the right flank with 3-3 x 105 tumour cells
and 2 x 106 lymphoid cells in 0-3 ml
HBSS. Tumour cell-lymphoid cell mix-
t-Lires were held on ice until injection.
Eight independent experiments tised
tumour-derived lymphoid cells, and the
results were pooled (Table 1). Overall,
admixture of Mc7 tumour-derived lym-
phoid cells with viable sarcoma cells
markedly reduced the tumour incidence
in comparison with medium-treated
sarcoma cells (P
= 4
-9 x 10-7).
Whei-i these experiments were taken
individttally, there was significant reduc-
tion in tumour incidence in 5 of the 8
experiments, but in. 2 of the remaining 3
tumour growth was retarded in i-ats
treated with tumour-derived lymphoid
cells. Normal spleen cells failed to exert
any anti-tumour effect at the same
lymphocyte:sarcoma cell ratio, and pre-
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TABLE I.-IFinn a88ay8
derived lymphoid cell8
8eparate experiment-8)
u8ing tumour-
(data froni, 8
P for
tumour
inei-
dencet
0-13
4.9 x 10-7
0-28
Source of Ttimotii-
lymplioid itici-
GI-oup cells dence*
I Mectium (control) 49/55
2 Normal spleen 24/30
3 Alc7 tumour 19/45
4 Normal spleenj 25/27
O" Rat.s /O
Nvl'tli
tumoui-s
89
80
42
93
*Rats were observed until tun-iours reaclied
3 cm in diameter, wlien the animals were killed.
Animals in wlileli tumours failed to grow were
observed for at least one furtlier month.
t By Fislier exact test, in comparison witli meditim
coiitrol group.
I Trypsinize(I and nyloii-columii-treate(I in paral-
lel Nvith tumour-derived lympliold cells.
treatment of these spleen cells with
trypsin and elution from nylon-fibre
columns failed to make them inhibitory in
the Winn assay.
The Figure illustrates an experiment in
which the effects of the tumour-derived
lymphoid cells were titrated. The inost
pronounced effects on tumourgrowth were
obtained with a 6: 1. effector taroet ratio,
10 20 30 40 50 60
Days after injection
FIG.-NN"itiii assay of sarcoma Ale7-derlved lympliold cells, usitig 3-3 x 105 sarcoina Alc7 target cells
per inoculi-im: 0-0 target cells+rnedium (7/7 rats xvith tumours); A-A normal spleen cells+
target cells, 6:1 ratio (7/7 rats witli tumours); E-0 tumour-derived lymphold cells+target cells, 6:1 ratio (2/6 rats witli tumours); x x Tumour-clet-lved lymplioi(I cells +target cells,
3:1 ratio (3/6 rats -vvith tumours); *-* Tumour-derived lympliol(i cells+target cells, 1-5:1 ratl(
(3/6 rats %vIth tumours);
TLIMOIII'groxvth curves were plotte(I tiiitil i-at(s) Nvithin tite, gi-otil) Nvere killed,%vith tumoursexceedilig 3 cin diameter.
Note tliat, the tumour-derived lympliol(i cells iiot only reduce the growth rate btit also ctelay the
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but even with a ratio of 1-5:1 significant
reduction in tumourgrowth was observed.
We are not aware of anv previous
demonstration of the control of in vivo
tumour growth by cells derived directly
from within a growing tumour. Tumour
inhibition has been reported using a
chemically induced guinea-pig sarcoma
(Berczi & Sehon, 1977), but in this case
the effector cells were derived from
2-3-week culture of tumoui- lymphoid
cells which had been re-stimulated in
vitro. Our studies show that otherwise un-
treated purified tumo-Lir lymphoid cells
can control tumo-Lir growth when niixed
with sarcoma cells at an appropriate ratio
(in this case as low as I -0- effector cells per
tumour cell).
The Winn assa nii(yht be criticized as
an unsuitable method for demonstrating
anti-tumour effects in vivo, although in
o-Lir experiments the use of effector cells
from within an s.c. tumour site would
appear to justify using an s.e. mixed
inoculum of tumour cells and lymphoid
cells. Furthermore, the eontrol of tumour
growth in Winn assays is not a simple
reflection of the in vitro anti-tumour
effects of the lymphoid cell preparations
used. Thus spleen and tumour-derived
lymphoid cells both show strong cytotoxic
activity against cultured tumour cells in
6h and 18h 51('r-release tests or a 48h
[75Sel-selenomethionine microcytotoxicity
test , although only tumour-derived
lymphoid cells were effective in the Winn
assay (Robins & Flannery, in prepara-
tion). Similar laelt of correlatioii between
in vitro assays and Winn assays has been
found in a number of tumour systems. For
example, Howell et al. (1974) found that
spleen cells from mice imniunized to an
8V40-induced tuino-ur were sometimes
active in a microcytotoxicity test, but in-
active in a Winn assay. Similarly, Burton
& Warner (1977) found no clear correla-
tion between the activities oflymphocytes
induced in vitro to mouse plasmacytomas
in 5lCr-release tests and Winn assays.
Macrophage-mediated antitumour effects
detectable in vitro may also not be fune-
TABLE 11.-COMpari8on of in vivo-derived
and cultured Mc7 target ceI18 in a ll'inn
a88ay of Mc7-tuniour-derived lymphoid
cells
Source of
Alc7
target eells
I
In Vivo
Cultured
Sotii-ce of
lympliol(i cells
Ale(iitim (control)
Spleen*
NIc7 tumour
Afedium (control)
,-,pleen*
AIc7 t,urnour
Tumotir
iiiel(lenee
6/7
5/7
0/6
6/6
6/6
0/6
Spleen cells froin iiormal rats, ti-ypsinized aii(I
n I ylon-column-treated in parallel Nvith tiimotir-
derived lymphoid cells.
tional in vivo in Wiiiii-tvpe assays (Evans
et al., 1978). Cultured iumour cells have
also been itsed as target cells in Winn
assays, aiid the results obtained were
comparable with those using target cells
from tumours grown in vivo (Table 11).
These findings further accentuate the
difference between Winn-type assays and
in viti-o tests, and also provide evidence
that the host lymphoid cells present in the
i?i vivo-derived target-cell preparations
are iiot required for the tumour-inhibitory
effect initiated by admixed t-Limour-
derived lymphoid cells.
The specificity of the anti-tumour
effect of tumour-derived lymphoid cells is
currently under investigation, although
logistic problems in the preparation of
sufficiently large nunibers of tumour-
derived lymphoid cells for the appropriate
i-eciprocal testing between different
tumours make these tests difficult to
perform. The results of these studies will
be of special interest in view of the indi-
vidually distiiiet tumour rejection anti-
gens present on these tumours. The nature
of the effector cell responsible for these
effects is also tinder study. Relevant here
is the detection within our tuniour-
derived lymphoid-cell preparations of cells
with the specificities of natural killer cells,
and of ADCC effector cells, at least in
short-terM 51(ir-release assays (Flannery
et al., in preparation); similar results have
been reported in other systems (Moore &
Moore, 1979).TUMOUR INHIBITION BY INTRINSIC LYMPHOID CELLS 949
A further possibility is that, during the
separation procedure, tumour lymphoid
cells have been freed of a suppressor-cell
population, or have recovered from an
anergic state; further studies on these
points are in progress.
We thank 0. F. H. Roberts for technical assis-
tance. This work was supported by a block grant
from the Cancer Research Campaign.
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